AUS-131 and Patents
At Ausio, we are working to discover and develop products to improve patient outcomes throughout the world. Our lead compound, AUS-131, is a first-in-class, nonsteroidal, nonhormonal, small molecule (S-equol) that has higher selectivity toward estrogen receptor β (ERβ) than to estrogen receptor alpha (ERα). Two Phase 1 studies have seen completed and published; AUS-131 was safe and well tolerated in humans. A Phase 2a trial in menopausal women with vasomotor symptoms (VMS) has been completed and a Phase 2a trial in men with benign prostatic hyperplasia (BPH) has been completed.
Patents
Ausio Pharmaceuticals has a strong patent position for S-equol.
US 7,396,855; US 7,960,432; US 8,048,913
Issued July 8, 2008 (Expiry December 3, 2024)
Composition and Products Containing S-equol, and Methods for their Making
US 7,528,267; US 7,960,573; US 8,263,790; US 8,716,497
Issued May 5, 2009 (Expiry January 27, 2027)
Method for Enantioselective Hydrogenation of Chromenes
AUS 2006275587
Method for Enantioselective Hydrogenation of Chromenes
AUS 2002359220
Issued December 15, 2008 (Expiry July 24, 2023)
Compositions and Products Containing Enantiomeric Equol, and Methods for their Making
China 200680036577.1
Method for Enantioselective Hydrogenation of Chromenes
China ZL03822155.1
Issued May 26, 2010 (Expiry July 24, 2023)
Compositions and Products Containing Enantiomeric Equol, and Methods for their Making
Japan 5507081
Method for Enantioselective Hydrogenation of Chromenes
Japan, EU, and others Pending Office Action
US Anhydrous Crystalline Form of S-Equol 14,883
|
|
